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THE PHAfuv,AGOW:nC TH1-:J\.TIILSNT OF AUHIGULAR F j . .BRILitATION 
INTRODUCTION 
Auricular fibrillation is the most common of all marked 
irregu.larities of the heart beat in Qrganic heart disease. 
For this reason, and because of the gratifyin,~ results one 
achieves from its treatment, I have chosen this subject as rry 
topic. 'rhere will be no at tempt on the part of the student 
to discuss the etiology, diagnosis" complications, or 
incidence of this condition. The mechanism of auricular 
fibri llation if Jill be discussed as briefly as possible only to 
more fully understand the rationale of its treatment. 
1 
There are four principal theories which have be;,m advanced 
to explain the physiology of this condition. 
They are: 
1. a rapidly beating ectopic pacemaker 
2. multiDle rapidly beating ectopic pacemakers 
3. continuous mult,iple reentries initiated by a single 
or multi ole i~pulses 
4. a self-perpetuat.ing mother ring caused by a sin'Sle 
initial imp-ulse 
At present the la~ter of these theories is the one most 
1I'l:i.dely accepted. In a review of the literature one finds 
convincing arswnents both for and as;ainst each of the above 
hypotheses. HOV'T8ver as far as treatment of auricular fibrillaLion 
is concerned, these theories are laYgely academi.c. The 
import.ant thing to realiz,e is that this condition is due to 
the passage of excitation waVes through the non-refractory atrial 
syncitiwn in an asynchronous fashion. 'rhus it rr.ay be eradicateo. 
either by an over-all prolongation of the refractory phase 
making the chamber unresponsive to the impulse, or by increasing 
the speed at which these imDulses travel 80 that they would be 
obliterated by arriving at regions before the absolute 
refractory phase I-Jas over. 
2 
The treat.ment of atrial fibrillation has been and sdll 
is a challanging problem. There are three general types. 
They are: chronic, acute, and thyrotoxic auricula.r 
fibrillation. The treatment of this condition (with the 
exception of the latter tyne) consists mainly in the use of 
three drugs--dL<;italis, quinidine, ar.d pronesGYl. Atabrine, 
fagarine, and chloroquine have been used, but vdth less 
success. 
Treatment of thyrotoxic atrial fibrillation consists of 
treatment of the underlying or excit.ing condition. 
Anti-coagulant drugs are 1.B ed to treat a c~)mplication of 
this lesion. '1'his will be discussed below along withithe 
drugs of choice. 
Anti-thyroid Drugs 
In most cases the above mentioned drugs aYe not so 
useful in the treatment of th:rrotoxic atrial fibrillation. 
One must treat the underlying or basic lesion, and in this 
instance therapy consists of the ant.i-thyroid drugs. 
For imr:cediate action, O. 5gm. of sodium iodine may be 
given. This should be followed by Lugol's solution in oral 
dosage along with appropriate antt-tl1yroia t.nerapy. 
Once the patient has been rendered euthroid by anti-
t.b ..yroid procedures, his cardiac problem is alm03t always 
resolved" If sl~ch is not the case, quiniaine is indicated, 
3 
and has been found oarticularly us eful in this instance. 
Di~itali~ 
For many yea.rs digitalis w-as looked upon as influencin,s the 
heart chiefly through slowini5 t:.he cardiac raGe, and was 
hence thought specific for the treatment of atnal fibrillat.ion. 
instead of being a specific anti-fibrillatory drug, digitalis 
has in fact just the opposite effect.· It actually increases 
the rate of atrial fibrillaGion by a shortening of the 
refractory period thereby allowing a greater rm.mber of 
exci;:,a~L;n waves to pass through the auriele. 
Digitalis is administered not as a CIre Lr this con-
dition, but merely as a cODljrul for it. This drug is utilized 
primi:i.rily to control the ventricular response in ;Jresenee of 
atrial fibrillation. It prevenc,s this conditlon from gOlng 
on to ventricular tachycardia ard/or ventricular fibrillation, 
b..:;th of \'lihlch have grave consequ8Eces for the patient. rhe 
dru.g accomplishes this c'.:ntrol phenomena by its action in 
decreasing the conduct.ion .in the atrioventricular node and bundle 
of His. Thus a pharrnacolo:;;ic block is formed to protect the 
ventricles. 
Dif~italisls also used with this condition because of its 
beneficial effect upon carciiac function~ This often alleviates 
the anginal and/or cerebral ischemic symptoms frequently found 
with atrial fibrillation. 
4 
This drug is being 'lsed le8':) often tociay for tile treatment 
of atrial fibrilLation. 'l'his is becal.se thera()y is much less 
conserva-sive than before. A more agressive atsack is being advo-
cated with physicians being less selective in the patient t:.hey 
try to conve:rt with the spacihc antifibrillatory dnigs. 
IIDigita1.ls is mainly indicated in the preser;ce of 
congestive cardia.c failure, cardiac enlarseElent, in cases with 
rapid ventricular rates, and in cases \-Jhere conversion to sinus 
20. 
rhythm vii t h quinidine has failed. !I 
Classically, control is considered adequate when ['he h(~art 
rate is maintainec. around 85 beats per minute, without appreciable 
increase in rate with moderate exercise. .qS with other cardiac 
conditions where digitalization is indicated, dosage ,nnst be 
indiv::l.dualized. The resultircg variations in cardiac reSiJonse 
are related not only to the different characteristics of the 
glycosides, but also to differing responses by individual 
Datients. 
Since there is ::nch a fine lir:e bet~feen adequate 
di~italizati':)n and toxicic.y, one must always be alert for 
digitalis excess in trea::.ing this condition. 'I'he several ob-
jec Give clues ",;hich may harn the physician of the presence of 
excess digitalis are: "l. further acceleration oi the ventri-
cular rate following di:?;italis admini3tration, 2. obvious 
independent activation of atria and ventricles (inordinately 
5 
.,,-
slow, rapid, or precisely regular ventricular rates should be 
" 3 sllspec:~8a), • obvious group beatim; (bigeminy, trigeminy, 
quadrageminy), 4. determination of the rate of the accelerated 
11. 
nodal pacemaker to be b8t"veen 70-130 beats per min'J.te. II 
'oluinidine is ;,he traditio:,al drug of choice for ttll?-
treatment of atrial fibrillation. "In apPl'oxima,tely t,nree 
fourths of the cases, quinidine is neces:3ary to effect revision" 
to a normal sinus rhythm. 
This drug El,cts as a myoca,rdial cJepreS3art. According to 
27. 
vveisman ~~ depresses the sinoauricular node, increases the 
refractory period, a.nd decreases ccmducT.ion time. It causes 
a prolongation of the P-H, QRS and S-T intat'vals. 
Recently th.ere has been a great deal of controversy over 
12.. 
the selection of pat;i;.ents for conversion from atrial fibrilLation 
to sinus rhythm. Thou'Shts varied from those who felt that 
conversion should be attempted in all instances to ::'h088 who 
rejected conversion to normal sir:us rh;ytb...:m in all cases. The 
reasons for the latter opinion appear to be d~e to t:,e belief 
that tliere is V6 Y Y lit:~le supe.riori'~y of simls rbythm over 
di<sitalis controUed fibrillation, and a fear of the toyic 
effects of quinidine. 
Toxic side effects of quinidine inclu_oe "" a; group of ' 
symptoms knovm as cinchopism--tinnitus auriw;J, blurring of 
vision, vertigo, tremor, and light-headeoness as well as gastro-
6 
15. 7. 
intestinal disl.:.ress.'! Reports have also linked this aru.g 
with the development of thrombocytopenic purpura. 'fhe ~tl.ore 
serious complicat,i,)ns of quinidine are nroblably the cardiac 
19. 
arryt.hmias it produces. These incl'lde S-A and AV blocks, and 
ectopic rhythms of atrial, nodal, and ventricular origin. 
Death during the course of quinide therapy is often due 
to either asytole or respiratory oaralysis, neit,her of l,"hich 
is too surprisin~ in view of the fact that it ir.hibits acetyl 
/ 
b. 
choline which is thought to initiate the heart beat. A myo-
cardial and respiratory depressing agent is given to an 
already embarrasseC' myocardium and a physiologically impaired 
respiratory center. 
A healthy respect for quinidine is of COUrse understandable 
in view of the fact that it is in reality cardiotoxic and 
deaths have been reported in therapy. In view of the beneficial 
results attained with Draper quinidine therapy, it would appear 
that the fears are la.rgely unfounded, especially if the proper 
precautions are observed~ 
4. 
Brill urges that the following precautions be utilized 
when converting a patient with quinidine. 1. Do not administer 
this drug until full digitalization with a ventricular rate 
of 80 or lower and n~xium compensation is achieved. 2. Rule 
out abnormal sensitivity to the drug with a 200 mg. test dose 
on the day prior to the full dosage schedule. 3. Do not 
7 
fSive if the QRS is~sreater than 0.14 sec. 4. Before each dose, 
examine the patient and if hypotensive, or if there are 
significant si:sns or symptoms of toxicity, st,op the drug. 
5. Frequent EKG's should be taken to dectect QR3 widening, 
A-V dissociation, or cOYflplec:.e A-V block. 
The advantages of sinus rhythm were well documented by 
8-10. 
Corday who demonstrated using catheter techniques that atrial 
fibrillation vIlth a rapid ventricular rate resulted in a reduction 
in coro:nary artery flow, a les3ening of cerebral blood flow, 
and a deminution of renal and mesenteric artery flow. In 
clinical observa.t.ions:~they have further sho1tm t,bat relief of 
symptomatology (anrsirrl., dizziness) -which follov,s a normal sinus 
rhythm can be correlated with improvement in blood flow to the 
affected parts. Patients have been reported who, before 
conversion, had resoonded poorly to digitalization, became 
free of symptoms after the establisDJ11ent of a normal sinus 
rhythm. 
It seems to be [,he consensus of opinion at this Gime that 
conversion from atrial fibrillation to a normal sinus rhytJ:Iffi 
should be attemptsd in all cases, except those in l'fhich a 
contraindication to quinidine exists. This drug is contra-
indicated when there is a coexistant intraventricular condu.ctiol1 
defect or bundle brar~ch block, or ",hen atrial fibrillation is a 
resutl of over-digitalization. Quinidine is generall,y rejected 
when sev",re congestive failure or v,hen the heart is severely 
enlarged, and also when aerial fibrilla:,ion relieves 
precordial pain;'. 
Quir>idine is best adnLLnistered via the oral or B'l route. 
IV quinidine ac1Jnini:3tration is !'raught vdth 30 much hazard 
that admir>istra,tion by this aV8Lue has lar~ely been adbandoned. 
in one series in which quinidine vJas given i ntravenou. sly , the 
1. 23. 
mort,ality rate 1NHS 10%. Soko1mil studied the effectiveness 
of quinidine in the treatment of cardiac arrythmias and 
correlat.ed serum levels with effective treat,ment. The avera.ge 
serum concentration which 75-80 per cent of patients "Ii"l/ith 
atrial fibrillation converted inlaS 5.4 mg. per liter. This level 
vias achieved by aOlllinisLering the drug every t"m hours. Thus, 
it is lriidely accepted that the drug be given in divided doses 
4. 
at two hour intervals. Brill recommends that quinidine su.lfate 
U.S.P. be given hOO mg. five or six times dail~T for the first 
day. On each of the follovdng two days, providing the 
arryLhrria continues and no toxic synwtoms appear, the dose is 
increa.sed by an increment of 200 mg. The dose ITIr3.Y be continued 
for aofourth day v'Iithout change in dosage. The drug is usually 
not continued beyond the fourth day. If conversion is not 
achieved, a second and even a third attempt. may be atLempted at 
intervals of several weeks. rrhis meshod ha s met a high degree 
\ 
of success with Vc::)Y'Y little toxicity if the preVIOusly described 
prec1'Htions are adhered to. Jllaintenance is largely a matter 
9 
of trial and error. Unfort1.matel:r, no truly effective anecdote 
16. & 19. 
is not available for oVE:Or-dose of quinidine. 
It is no longer felt that a Jrev:bous hisGory of embolism 
contrainclicat'!s revision of a nOrlEal sinus rhythm through the 
3. 
use of ccuirddine. The risk of an embolic episode in the natural 
course of atrial fibrillation is considered greater than it is 
during conversion to sinus rhythm using quinidine. In patients 
with a previous history of embolism, a cour-se of anti-coagulant 
therar)Y is sl:,rongly recorrnnended as a prophylac I:,ie measure. 
Prones.tyl 
This drug is a comparatively new adcit.ion to the physicians' 
armamentarium used against atrial fibrillation compared to 
i" -"-,./ . 
quinidine. It produces in man a delayed conau.cGion rate and a 
prolongation of the refractory period. 
The posiLion of pronestyl in the treatrre nt of atrial 
fibrillation appears m,Jre or less limited to the treaGment of the 
18. 
paroxysmal variety of this condition. In one series, recent 
atrial fibrillation (less than two weeks) responded to treatment 
in 8-8% of the cases while the chronic variety (more than two 
weeks) was treated suecessfull~v in only 21% of the cases. Also, 
in view of the limited experience we have wiLh procaine amide 
as compared to quinidine, it waul·:} a'OiJear that the former drug 
should be'J.sed \-/hen the latter cannot be tolerated. This drug is 
especially effacious in the treatment of acut.e atrial fibrillation 
10 
25. 
since it may be aCJIrLnistered IV l,'fiTJh less danger than quinidine. 
Contraindications and precautions to the use of pronest.yl 
are essentially the same as those for quinidine. 
Toxic side reactions have occurr<;3d involving the circulatory, 
gastrointestinal, and central nervous system. Ventricular 
extrasystoles, ventricular tachycardia, and even ventricular 
2. 
fibrillation may occur. Falls in BP during IV administration 
have occurred in a number of patients, mostly those alreihdy 
sufferini2; from a degree of hypotension with ventricular 
tachycardia. Gastrointest,inal syr!1ptoms include anorexi~, nausea, 
17. ' 14. 
and vomiting. Chills and fever and a drug rash have been 
reported as well. 
Kaydens recommends the following more or les3 general 
dosa~e sc:~edule. l"1it.h this drug as "lith other antifibrillatory 
agents, individualization must be made.wing the EKG as the 
main criterion of administration. When pronestyl is administered 
intravenously, it should not be:siven more than IJO mg. per 
minute. The d03e i3200 to 1,~)OO mg. via this route. Orally, 
the drug is given in capsules of J.25 gm., 1-2 capsules every 
1+-6 hours. Intramuscular ly, it is rec ommended that it be given 
one gm. four times a day. Naintenance dosage should be continued 
for aporoximately four weeks after revision to normal sinus 
rhythm. The latter dosage schedule is again emperical. 
other I~rugs 
Due to the existence of the rel~tively safe, effective drugs 
11 
disc1J.S3eci (dL>;italis, quinidine, and prones Jyl), the dru.gs listeo 
belNi have achieved little popularity. They are mentioned 
mainly for the sake of completeness. 
Atabrine 
Atabrine acts in much the same manner a,s quinidine, by 
increasin..-g the refractory period of the myocaroium and by 
decreasing its excitability. This is not surprising as quin:ine, 
the classic anti-malarial drug, v,as the first really successful 
anti-fibrillatory drug used. 
This drug is especially useful when quiro.idine .,as failed 
24. 
and with Datients who have coronary heart disease, 
The dose is fromO.l to 0.2 gms. dissolved in 10-20 r.1l. of 
normal saline, given by injection. 
The us e of quinacrine is limited becaJ_se of its propensity 
to cause ventricular fibrillatic,n. Also, there may be a yellow 
di;3coloration to the skin due to the deposition of an acridine 
pigment. 
Fagarine and Ghlorocluine 
These drugs have also be:,n found ,~o have anwi-fibrillatory 
21. & 22. 
properties. This property, like that of quinidine, and atabrine 
was found incidental to the treatmerrt of malaria. It is felt 
that these drugs act by deer-sasing the excitability of the 
myocarclilJIlJ; hmveVel', thlS action has noe bE<:m proven In man. 
They are adrrlini:3tered inesl'venously ln order to be effective 
12 
21. 
in the revision of sinus rhythm. hov,ever, a safe dosage 
schedule has yet to be worked out. 'The incidence of fatal 
ventricular tachycardia and fibrillation in these drugs has 
")') 
,:.. .. "-. 
been too hi:sh for them to be of much use. 
13 
SUhl':..4.EY 
This paper deals, as far as possible, solely 1rr.i.:th the 
pharmacolo2;ic treatment of atrial fibrillation. The basic 
mechanism of this condition is pointed out only to edify the 
reason for the successful action of the antifibrillB.tury drugs. 
The drugs discussed were di:sitalis, quinidine, and. pronestyl. 
Atabrine, fag;arine, chlor0quine, and the treaUilent of 
thyrotoxic atrial fibrillation are discussed briefly. 
Treatn:.ent of thyrotoxic atrial fibrillation consis ~~S of 
treating the basic disease process, thyrotoxicosis. For 
im:rr;ediate action, 0.5 :9ll. of sodiu.'11 iodide is given IV. This 
is fo1101-,eo by appropriate anti-thyroid. treatment. 
It was pointed. ')ut -+:'hB.t ciigitalis is not a specific 
treatment for this condition, but merely a Itcontroll' for it. 
It prevents atrial fibrillation from going on to the more 
serious ventricular tachycardia and/or fibrillation. The 
drus accomplishes this control mechanism by creating a 
pharmacolo:.sic block in t.he A-V node and b-lndle of His. It is 
also utilized because of its beneficial effect on cardiac 
out,put. Classically, control is considered adequate yo[hen the 
ventricular rac:.e is kept a.round 80 beats per minute with no 
aporeciable increase in rate with exercise. Dosase must be 
individualized in order to achieve adeq'.1ate control and yet 
avoid the o)itfali of digitalis int,oxication. Several objective 
C1..ues to alert the physic:ia n to this hazard are listed.. 
Quinidine, the specific c-riJ_Z in the treatment of atrial 
fibrillation, . is discussed in some detail. It can !l curs" the 
condition, nOG merely II control" , it. Some controversy 6y,iST,S 
today in the selection of patients for the. revision of normal 
sinus rhythm. The old argunmnts that quinidine is to be feared 
and that sinus rhythm is little superior to digitalis controlled 
atrial fibriEation have largely been disproven. Experimental 
and clinical experiences ha. ve shovm the clear cut superiority 
of a normal sir-us rhythm. Also, if the listed precautions are 
observed, the fears of quinidine are largely unfounded. It would 
seem that unless one of the recognized contraindications exist, 
conversion from atrial fibrillation to normal sinus rhyt,J:lrH 
should be attemptec: in all instances. A dosage schedule and the 
rationale for the schedule are disGussed E,.long ",;-ith a fe\llJ 
ftiords conc~:rning en,bolsim during revision of the physiologic 
heart beat. 
It "fas pointed out that prorlc33tyl has much the same mode 
of aCGion as does quinidine. It is oest U3 ed when the patient 
cannot take quinidine, and when the arrhythmia is acute in 
nature. Contraindications ard orecautibns for this drug are 
much the s["me as those for quill.i.dine. An added value is that 
pronestyl can be given IV much safer than rng.y quinidine. Also, 
a fairly effective anecdote is available. A rough dosage 
schedule and its untO"l'iard effects are discusseG. 
The other drugs useo_ in the treatment of this condition--
J!.5 
atabrine, fa :sarine, a.nd chloroquine \~ere discovered incidental 
to malarial therapy. They have met little )opularity because 




1. 'fhyrotoxic auricular fibrillation is best treated by 
attacking the basic disease process 1r.ith anti-thyroid 
therapy. 
2. Digitalis is indicated to ilcontroli' auricular 
fibrilJ_ation and to prepare the patient for revision to 
norrnal sinus rhyt.hm. 
3. Revision to normal sinus rhycrm should be attempted 
in all incidences unles3 there is a contraindication to 
the use of quinidine (and pr<::mestyl). 
4. PronesT,yl is indicated when quinidine cannot be tolerated 
by the patient, and in the revision of acute fibrillation. 
5. Fagarine, chloI'o.-'l'J.ine, and atabrine have met ltJith liGtle 
popularity in the treatment of auricular fibrillation 
because of their tendency to cause ventricular tachycardia 
and/or fibrillation. 
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